JPS5883971A - Production of urine guide cathetel having capacity preventing infection of urinal tract - Google Patents

Abstract

(57) [Summary] This bulletin contains application data before electronic filing, so abstract data is not recorded.

Description

DETAILED DESCRIPTION OF THE INVENTION The present invention was made using an olefin polymer, a diene polymer, or a silicon polymer as a material. The present invention relates to a method for producing a urinary catheter having the ability to prevent urinary tract infections.

Patients after surgery for spinal cord injury, cerebral hemorrhage, and encephalomalacia9 are often accompanied by symptoms such as difficulty in urination and urinary incontinence. In such situations, urinary catheterization using a catheter is used to ensure a smooth urinary tract, thereby promoting maintenance or improvement of renal function or preventing urine leakage. The catheter used in this case is particularly called a urinary catheter.

For its intended use, it is required to have sufficient flexibility, elasticity, and harmlessness to the human body, and is usually made from olefin polymers, diene polymers, or silicone polymers.

Urinary catheterization is an extremely useful treatment method that allows prompt urination, so it is used not only in urology.

Although urinary catheters are frequently used in fields such as surgery, internal medicine, and obstetrics and gynecology, there is a problem in that once a urinary catheter is placed in the urinary tract, infection is inevitable. In other words, since urinary catheters are left in the urinary tract for long periods of time, bacteria can enter through the catheter.
Symptoms such as urethritis, cystitis, and nephritis occur frequently. If the conventional open continuous urinary catheterization method (a method of collecting urine in an unsterilized container such as a glass bottle) is performed.

It has been reported that infection occurs in 42 to 80% of cases within three days, and infection is established on the gold side on the seventh day.

For this reason, methods such as cleaning the bladder and injecting disinfectants have been used to prevent urinary tract infections, but they are cumbersome and difficult to operate.
There are many unfortunate aspects, such as operating the box octopus itself can become a new source of infection.

Chemotherapy, such as prophylactic administration of antibacterial substances, is also used, but side effects can occur even with large doses or even small amounts depending on the type of antibacterial substance, and bacterial replacement may occur if infection occurs. There is a strong desire for local use of antibacterial substances, to the extent that unplanned chemotherapy is said to be harmful due to the effects of watermarks.

Regarding the topical use of antibacterial substances, there are methods such as applying an ointment containing antibacterial substances to a urinary catheter, coating the wall surface with resin and impregnating this coating layer with antibacterial substances. No. 27680) has been proposed, but in these methods, the antibacterial substance is only adsorbed to the support layer, so the antibiotic is washed away by urine and flows out of the body within a very short period of time after being indwelled in the body. It cannot be used satisfactorily because its antibacterial function is no longer recognized.

Another local treatment method is to instill a diluted antibacterial solution directly into the bladder using a so-called three-way catheter.

Because it is difficult and cumbersome to handle, it is currently only used in some urology departments and not in other clinical areas.

The invasion routes of #II bacteria are: ■ Retrograde through the gap between the urinary catheter and the urinary tract mucosa (extraluminal route), ■ Invasion from the M junction between the urinary catheter and the duct (including procedures such as cleaning A), (
3) Retrograde movement from the urine storage area to the inside of the conduit and urinary catheter (
There is an intraductal route). In the case of invasion through the extraluminal route, bacteria resident in the urethra quickly ascend along the wall of the urinary catheter early after placement.

reaches the bladder neck. Against such infections, the antibacterial substances present on the wall of the urinary catheter can exert an antibacterial function because they can come into direct contact with bacteria.

However, in 9 cases of intraductal route, for example, entry from the urinary collector,
In other words, bacteria that fall into or invade the urine collector proliferate in the stored urine, and reach the bladder as the urine flows backward and air bubbles rise. In particular, it has been confirmed that bacteria can be traced back to urine.

In case of invasion from such a route, the antibacterial substances present on the wall of the urinary catheter may not be able to come into direct contact with the bacteria, so the corner area where bacteria remain, which has no antibacterial function, may is high, and its ability to prevent infection is not sufficient. In order to have the ability to prevent infection from all entry routes, antibacterial substances must not only exist on the wall of the urinary catheter, but also gradually leave the wall and diffuse into the urine. It is necessary to come into contact with bacteria floating upward within the floor. In this case, the speed at which the antibacterial substance leaves the wall surface becomes an issue. In particular, methods such as adsorbing antibacterial substances on the urinary catheter, coating walls with antibacterial coatings or coating the walls with resin, and impregnating this coating layer with antibacterial substances are used. In this case, the antibacterial substance is easily washed away by urine and flows out of the body, and in a very short period of time, it no longer exists on the wall surface even in the stuttering urine. This means that the ability to prevent infection is completely lost after being left in the body for an extremely short period of time. Therefore, the ability of the antibacterial substance to control the speed at which it leaves the wall surface,
Maintaining the concentration of antibacterial substances in urine above an effective concentration over a long period of time is important for preventing infection.

In view of the current situation, the present inventors have developed a urinary catheter that is easy to use, does not become a new source of infection, and has the ability to prevent infection from all entry routes over a long period of time. As a result of extensive research with the aim of providing antibacterial substances, we have found that antibacterial substances are bonded to the reaction product of a specific maleic anhydride copolymer mixture and a polyfunctionalized ornament that can react with the mixture. The inventors discovered that the antibacterial substance gradually separates from the reaction product when the urinary catheter is exposed to water, and succeeded in applying this phenomenon to urinary catheters, resulting in the present invention.

That is, the present invention applies to the inner wall 1 or the outer wall of a urinary catheter made of an integrated olefin thread M-8, a diene thread polymer, or a silicon thread wheel integrated.

(f) A copolymer of maleic anhydride and an aromatic vinyl monomer or olefin monomer capable of co-electrifying therewith [hereinafter abbreviated as component (1). ] 05-995 heavy body [hereinafter 05
It is abbreviated as y and minutes. ]05~99,5-fold ht part and (A
1 to 200 parts per 100 parts by weight of the total amount of l component and 0 component
C) Polyfunctionalized ornament [hereinafter (CI acid component abbreviated)] of the car scenery part is reacted with the inner wall to form a film having unreacted maleic anhydride groups on the outer wall spanning the inner wall, and then This method of manufacturing a urinary catheter having the ability to prevent urinary tract infection is characterized by hydrolyzing a portion or all of the maleic anhydride groups and then bonding an antibacterial substance to the film.

The olefin polymer referred to in the present invention refers to a hydrogen-swollen polymer having one double bond, such as ethylene, propylene, 1-
Butene, 3-methyl-1-butene 5.3-dimethyl/
-1-butene, 1-pentene, 4-methy)v-1-pentene, 3-methy/l/-1-pentene, 1-hexene,
4-methy, 11/-1-hexene 5-methy1-1-hexene, 1-heptene, 1-octene, 1-decene, 1-
Hexadecene, 1-octadecene, vinylcyclopropane, vinylcyclohexane, isobutylene, 2-methylene/
L'-1-pentene, cyclobutene, norbornene, etc. are monopolymerized or copolymerized by a known method.

The diene-based polymer referred to in the present invention is a swollen hydrogen 9 having two double bonds, such as butadiene, isoprene, 1,3-
Pentadiene, 1,5-hexadiene, 1,6-hebutadiene, etc. are monopolymerized or copolymerized by a known method. As an exception, cis-1,4-g isoprene is widely present in nature as natural rubber, which is also preferably used in the present invention.

Other copolymerizable components include 9, for example, vinyl acetate.

Methyl vinyl ether, styrene, vinyl chloride.

Vinylidene chloride, maleic anhydride, acrylic acid.

Methacrylic/l' acid, acrylonitrile, methyl methacrylate, sulfur dioxide, vinylpyridine, chloroprene,
Examples include ethylene oxide and formaldehyde.

Examples of the silicon spinning wheel combination according to the present invention include dimethylpolysiloxane, methylphenipolysiloxane, cyanoalkylmethylpolysiloxane, and fluoroalkylmethylsiloxane, which have high elasticity, high strength, and are harmless to the human body. Dimethylpolysiloxane is particularly preferred.

As the Al component used in the present invention, maleic anhydride and an aromatic vinyl monomer that can be copolymerized with it, or a copolymer of 9-olefin monomer can also be used, but preferred are A copolymer of maleic anhydride and styrene or ethylene or imbutylene-spread polypropylene is used, and particularly preferred is a copolymer of maleic anhydride and the above monomer, with a copolymerization ratio of 1:1 to 1:1. 1:5 and molecular weight is 500-2,00
0,000 is used.

As the component (2) used in the present invention, an anhydrous maleic polymer can also be used, but preferred is maleic anhydride and vinyl acetate or methyl vinyl ether) or ethyl vinyl ether/L/-J. Copolymers of maleic anhydride and butanediol vinyl ether are used, especially copolymers of maleic anhydride and the above monomers, with a copolymerization ratio of 1.
= 1~1:5 Ashi molecular lid is 500~2,000,000
0 is used. KaigushaUsed in the present invention (C)
Two examples of ingredients are ≠ m10-ner + chemical compound, such as hexamethylene diisocyanate, toluene diisocyanate, xylene diisocyanate, phenylene diisocyanate, and isocyanate derivatives of aniline-formaldehyde. Polythioisocyanates such as mihexamethylene lentioisocyanate.

Polyepoxides such as glycidyl ether, diglycidyl ether of diethylene glycol, polyvinyl alcohol, polyvinyl alcohol, propylene, vinyl chloride, allyl alcohol, N-vinylpyrrolidone, etc., as well as methyl, ethyl polyvinyl alcohol.

Ether derivatives such as propyl, buty-p, octyl, dodecyl, phenyl, formal polyvinyl alcohol, acetal derivatives such as ethanal, butyral, aminoacetal, acetic acid, formic acid, etc. of polyvinyl alcohol,
Ester derivatives such as butyric acid, caproic acid, furic acid, stearic acid, benzoic acid, ethylene glycol, propylene glycol, butylene glycol, diethylene glycol) V, cyclohexanediol, pentaerythritol, glycerin, 1, 1,
1. - Polyols such as trimethylol-fluorobane and their carboxymethylated products, polyethylene glycol, polypropylene glycol, polytetramethylene glycol.

Polyether polyols such as polyethylene-polypropylene glycol and their carboxymethylated products, succinic acid, glutaric acid, adipic acid.

Dicarboxylic acids such as sepacic acid, isophthalic acid, phthalic acid, terephthalic acid, and ethylene glycol.

Polyesters with hydroxyl groups at both ends obtained by condensation of glyco-p with propylene glycol, butylene glycol, and their carboxymethylated products, natural polymers such as starch, ceratin, dextran, and their carboxymethylated products, monoethanolamine , amino alcohols such as triethanolamine, and polyamines. Examples of polyamines include low molecular weight polyamines such as ethylenediamine, trimethylenediamine, 1,2-diaminopropane, tetramethylenediamine, 1,6-diamiptan, 2.3-diaminophtane, and pentamethylenediamine.

2.4-diaminopentane, hexamethylene diamine,
Octamethylene diamine, nonamethylene diamine, decamethylene diamine, undecamethylene diamine, dodecamethylene diamine, tridecamethylene diamine, octadecamethylene diamine.

N,N-dimethylethylenediamine, N,N-diethyltrimethylenediamine, N,N-dimethyltrimethylenediamine, N,N-cyphyltrimethylenediamine,
N,N,N'-)diethylethylenediamine 9N-methyltrimethylenediamine, N,N-dimethy/l/-p-
Phenyl diamine, N, N-dimethylhexamethylene diamine, diethylene triamine.

13- Triethylenetetramine, tetraethylenepentamine,
Heptaethyleneoctamine, nonaethylenedecamine, 1
, 3-bis(2'-aminoethylamino)propane, bis(3-aminopropa)V)amine.

1.3-bis(3'-aminopropylamino)propane, 1.2.3. - ) lyaminopropane, tris(2
-aminoethyl/L/)amine, tetra(aminomethyl)
Methane, methyliminobisprohydramine, methyliminobisethylamine, ethyliminobisethylamine, N-aminopropyl-2morpholine.

N-aminopropyl 7m/-2-hibecolin, N-(2
-Hydroxyethyl/l/)) rimethylenediamine, xylylenediamine, phenylenediamine, piperazine, N
-Methylpiperazine, N-(2-aminoethylA/)ethanolamine, N-aminoethylhiverazine, N,N
, N', N'-tetramethylethylenediamine, N
.

Encyclopedia of Polymer Science and Technology
r 5science and'I'echnolOg)
') Vol. 10, p. 616), (II) Ethyleneimine.

Alkylene imine polymers obtained by ring-opening superposition of alkylene imines such as globylene imine [Encyclovidia Og Polymer Science and Technology, Vol. 1, p. 7'54].

(lll) In addition to polyvinylamine, polylysine, etc., polyvinyl alcohol and its derivatives are preferred from the viewpoint of biocompatibility and non-toxicity.
Polyols and polyether polyols are preferably used.

The antibacterial substance referred to in the present invention refers to antibiotics and bactericidal agents. Examples of antibiotics include cloxacillin, dicloxacillin, flucloxacillin, ampicillin,
Penicillins such as hetacillin, tarambicillin, cyclacillin, amoxicillin, bibmecillinum, and hiveracillin, cephaloridine, cephaloglycin, and cephalexin.

Cephalosporins such as cefathorin, cefavirin, cefrazine, ceftesol, cefoxitin, cefatridine, streptomycin, kanamycin, fradiomycin, paromomycin.

gentamicin, bekanamycin, ribostamycin,
dibekacin, amikacin, tobramycin.

Aminoglycosides such as subectinomycin.

Oxytetracycline, tetracycline, demethylchlortetracycline, methacycline.

Tetracyclines such as doxycycline and minocycline, macrolides such as elinuromycin, kitasamycin, oleandomycin, spiramycin, josamycin, and midecamycin, lincomycins such as lincomycin and clindamycin, mikamycin,
Gufmicidin S.

Antigram-positive bacteria such as gramicidin, colistin, polymyxins such as polymyxin B, biomycin, cabreomycin, enbiomycin,
Antimycobacteria such as cycloserine, amphotericin B, polyene macrolides such as pimaricin, rifampicin, virolnidoline, mitomycin C, actinomycin, pleomycin, daunorhiscin, doxorubicin, neocarzinostatin, etc. Aminoglycosides or polymyxins are preferably used because they are highly basic and highly effective against bacteria that cause urinary tract infections. Bactericidal agents include pigment preparations such as acrinol and acrylflavin, furan preparations such as nitrofurazone, and chloride pen-IJ')V.
Positive soap preparations such as Conium, Benzethonium Chloride,
Cyclohexidine, bohidone iodine and the like are preferably used.

To manufacture a urinary catheter by the method of the present invention,
First, it is necessary to react component fA), component (B), and component (C) on the inner or outer wall of the catheter to form a film on the inner or outer wall. For this purpose, (1) use an organic solvent as a medium to combine component (A) and (
Component B) and component (C) may be mixed, the inner wall casing or outer wall of the catheter may be brought into contact with this solution, and then the catheter may be heated. 17- Methods of mixing the three components include 1, for example, mixing the solution of the ^ component, the solution of the l component, and the OJ acid component Is solution, the method of mixing the solution of the component (c), and the solution obtained by adding a solvent to the component (iii). Any order or method can be used, such as adding the G+acid component or adding a solvent to a mixture of components (A), (B), and C).

In order to enhance the mixing effect and shorten the mixing time, it is desirable to heat or stir as necessary. Examples of organic solvents that can be used in the present invention include acetone, methyl ethyl chloride, aldehydes such as benzaldehyde, formaldehyde, and dimethyl formaldehyde, ethers such as tetrahydrofuran, and esters such as methyl acetate and ethyl acetate. + methanol,
Alcohols such as ethanol, propatool, isopropanol, and butanol can be used, but alcohols such as alcohols are preferably used. The solution thus prepared can be brought into contact with the inner or outer wall of the catheter by, for example, dipping the catheter in the solution, spraying the solution onto the catheter, or using a tool such as a doctor's knife or a "brush". You can choose a method as appropriate, such as applying it with a cloth.

After the solution has been brought into contact with the catheter in this way, the solvent is removed by drying, and then the mixture is heated in a housing preferably at 30 to 180°C, particularly preferably at 50 to 160°C for 5 minutes to 48 hours.
In particular, by heating for 10 minutes to 24 hours, the components 0 and q can be reacted to form a film on the inner or outer wall of the catheter. React at the outer wall (
The ratio of component A to component () and component (q) is 0 for component (A)
Component B) is 0.5 to 99.5 parts by weight to 5 to 995 parts by weight.
jii parts, (Q component is f'-) component and (1 to 200 Kamekura parts per 100 parts by weight of Bl component.Button component and (c)) component to the total amount of component. If the ratio is 0.511% by volume, the solubility of the resulting film in urine is too high, and the film will dissolve during long-term indwelling of r#11 in the body.

When it exceeds 99.5 weight:m:%, the ability to bind antibacterial substances decreases significantly, and '! Since the film forming property of F is also rapid, the proportion of component (1) is 05 to 995% by weight, preferably 20 to 995% by weight, particularly preferably 30 to 95% by weight.
It is necessary that If the ratio of component C) to 100 parts by weight of the four components and component (B) is less than 1 part by weight, the solubility in urine may be too high depending on the type or blending ratio of component (i) and component (). There is,
On the other hand, if it exceeds 200 parts by weight.

Not only will the ability of the resulting film to bind antibacterial substances be significantly reduced, but the film-forming properties will also deteriorate.

C) The ratio of the components is 1 to 200]i' parts, preferably 1 to 1
It is necessary that the amount is 150 parts by weight, particularly preferably 20 to 100 parts by weight.

In the present invention, it is necessary to leave unreacted maleic anhydride groups in the film formed on the inner or outer wall of the catheter. For this purpose, for example, the ratio of the functional groups of the maleic anhydride and (q component), the reaction temperature, and the reaction time may be adjusted as appropriate. A desired amount of maleic anhydride groups can be left unreacted.

In the present invention, it is then necessary to hydrolyze some or all of the maleic anhydride groups in the film obtained as described above. Hydrolysis is.

For example, a membrane-formed catheter with 10 to 10.0
This is achieved by immersing in water at a temperature of 40 to 100 degrees Celsius for about 5 minutes to 48 hours, preferably for about 1 to 10 hours.

In the present invention, it is then necessary to bond an antimicrobial substance to the film treated as described above. To bond the antibacterial substance to the membrane, for example, the bacterial substance is brought into a solution, preferably an aqueous solution, and this solution is sprayed onto the catheter.

A method of circulating this solution within the catheter or a method of immersing the catheter in this solution can be adopted. The binding of the antibacterial substance is preferably performed at a temperature of -10 to 60°C, particularly preferably from 0 to 50°C, for several seconds to 72 hours.
It is preferably carried out for 5 minutes to 48 hours.

The urinary catheter produced by the method of the present invention has properties ideal for preventing travel infections. That is, the period during which the swimming catheter /L/ is left in the body is most often 5 to 5 days.

21- The urinary catheter μ produced by the method of the present invention has a length of 2 weeks in some cases, and may be left in the culm for up to 5 hours. It has the ideal property of gradually releasing antibacterial substances into the urine over a period of time. Furthermore, it has ideal characteristics regarding release. In other words, the period when the infection rate is particularly high due to the resident bacteria of the urethra that are pushed into the bladder along with the catheter at the time of catheter insertion (if the catheter is inserted for such a long period) Clinically, it is released in large amounts in the area (which is common in some areas), and although the amount released decreases for a while after that, it is still released in an amount sufficient to prevent travel infections even after 5 weeks. have Although the characteristic of showing such a decrease in urinary tract infection cannot necessarily be said to be necessary from the viewpoint of preventing urinary tract infection.

From a cost-effective point of view, it is advantageous in that there is no need to use more antibacterial substances than necessary, which can occur when using reed antibiotics. This is a desirable property considering that there is little possibility that the ability to prevent infection will decline due to the emergence of resistant bacteria due to repeated use of large amounts22-, and such properties can be said to be ideal for a urinary catheter. If I were to explain this in a more concrete example, it would be as follows.

Aminoglycoside yarn antibiotic p produced by the method of the present invention
The urinary catheter attached to the urinary tube was immersed in constant deaf urine at 37°C, and the urine was replaced with the same amount of fresh urine every day for 40 days, and 40 urine samples containing antibiotics were collected. Results of measuring the amount of antibiotics contained in each sample.

1,500 to 40,000 for antibiotics in urine on the first day
p, g range, and from 1,000 to 35.g on the second day.
OOOpg+'day is 750-25. OOOILg,
Days 4 to 5 are 500 to 20,000 p, g, Days 6 to 7 are 250 to 15,000 g, Days 8 to 10 are 250
~10,000℃g, 11-14 days 250-7,
500℃g, 150-5. OOOPg
, 3.1 to 40 days were 100 to 2.500°Cg. As mentioned above, the amount released on days 1 to 5 is large, with the lowest case being over 500 pg, and on days 14 and 1, over 250 pg is released, and even on days 31 to 40. 1, which is considered to have the ability to prevent infection.
is being released.

In the present invention, the N) component used, however, the component: 10
) Depending on the type of component and the material of the urinary catheter, adhesive may be used as necessary to adhere the catheter to the film made of the reaction product of the ＾ component, (B) component, and υ) component. is possible. Examples of adhesion methods are 9, for example, a method in which a layer of adhesive is provided in advance on the inner or outer walls of the catheter, and each component is reacted on the surface of this layer, or a method in which the adhesive is mixed in advance with a mixture of each component. You can adopt methods such as keeping it in place.

The present invention will be explained in more detail with reference to Examples below. In addition, "part" in one example means 1-part by weight.

Example 1 Gantraz AN 169 (manufactured by GAF, Me+t
vhi = ivx - copolymer of til and maleic anhydride) 1
Department and SM A5.000 (ARCo Chemi
Copolymer of sti v;y and maleic anhydride) to ca1 company.
A silicone urinary catheter [Argyle Silicone, manufactured by Nippon Sharrad Co., Ltd.] was added to a solution of 1 part of Magrogor/l/400 (manufactured by Matsumoto Yushi Co., Ltd., polyethylene glycol/l/) dissolved in 27 parts of acetone. Foley
Catheter] was immersed in 3 molecules at room temperature, dried at 60°C for 2 hours, and further heat-treated at 140°C to give Ganzrez to the inner and outer walls.
A catheter having a coating made of a reaction product of SMA and magrogol was obtained. The catheter thus obtained was immersed in water at 70°C for two hours, taken out and air-dried, and then dibekacin sulfate aqueous solution [150 μ (titer)/1
00t+t) with a pH of 0. The catheter bound with dibekacin sulfate was damaged by scooping out IN sodium hydroxide and soaking it at 7°C for 2 hours while adjusting the temperature to 8°C.

This material was immersed in test urine at 37°C in a sterile oven.

After one day, test bacteria iCBacillus 5ubti
The antibacterial activity test for this trip was conducted using lis A'I'CC6633 by dropping 2 to 3 drops on the test rim onto a cylindrical plate using the cylindrical plate method, which produced an inhibition zone and showed no activity in the test urine. It has been reported that antibiotics may be necessary.

In addition, the amount of 25- Then, we repeated the same activity test.

The test edges collected on the 400th day also produced an inhibition zone and were confirmed to have activity.

Further, the amount of dipekacin sulfate released in the test urine obtained as described above was measured by a color quantitative method using sodium P-naphthoquinone-4 sulfonate. OOOILg+ 28.000℃g on the second day,
3 days day 23. OOOp g + 5th day i110,
000 Pg.

7,500 IL on the 7th day! J, the 14th day was 5,000 g, and the 35th day was 1,000 g.

Comparative Example 1 When a test similar to Example 1 was conducted on a catheter obtained in exactly the same manner as in Example 1 except that the operation of immersing it in water at 70°C for 2 hours was not performed, no inhibition circle was observed. There wasn't.

Comparative Example 2 A catheter bound to dipekacin sulfate was obtained in exactly the same manner as in Example 1, except that a solution of 2 parts of D Gantrez AN 169 and 1 part of Magrogol 400 dissolved in 27 parts of acetone was used. When this product was subjected to the same test as in Example 1, dissolution of the film was observed from about day 10 onwards, and it was judged to be unsuitable for actual application.

Comparative Example 6 2 parts of 5MA3000 and 1 part of Tuna Go p400
The coating of a catheter obtained in exactly the same manner as in Example 1 except that a solution dissolved in 7 parts of acetone was used was poor in uniformity. 1. When this product was used and dibekacin sulfate was added in the same manner as in Example 1, the same test as in Example 1 was conducted, and no inhibition circle was produced for the 58th test.

Examples 2-4 5 parts Gant, rez AN 169 and 95 parts 5M
900 parts of A3000 and 30 parts of triethylene glycol
1/3 of the catheter obtained in the same manner as in Example 1 except that a solution dissolved in 50% acetone was used, and 1/3 of the catheter was placed in water at 60°C for 4 hours.
After immersion, one bottle of gentamicin aqueous solution [150
I + v (titer) / 1oomg:), the other one in polymyxin B aqueous solution [1 million units 7100 m /], and the remaining one in frasiomycin aqueous solution (150 μ (titer) /
100g] at 25°C for 2 hours. 3 after soaking
Sample number corresponding to each antibiotic for this catheter
When the same test as in Example 1 was carried out using lft bacteria, the 40-day Ho tests obtained for all catheters showed an inhibition zone.

Example 5 Copolymer of maleic anhydride and ethylene (copolymerization ratio 1:1
2 molecular weight 500,000) 1 part, maleic anhydride and ethyl vinyl ether: 1, 1 part 100,000) and saponification degree 99.9 mol% polymerization, 11,700 polyvinyl alcohol/Lz 0. 5
A solution prepared by dissolving 10 parts of 1 part and 10 parts of acetone was placed inside a natural rubber urinary catheter (Argyle Foley catheter, manufactured by Nippon Sherwood Co., Ltd.) using a Verista pump at room temperature for 5 hours at a rate of 5 to 7 minutes. After the song cycle, 8
It was dried at 0°C for 1 hour and then heat treated at 150°C for 6 hours to form a film on the inner wall of the catheter. The catheter thus obtained was immersed in water at 60°C for 5 hours, taken out and air-dried, and then immersed in an I wt % aqueous solution of acrinol for 2 hours at room temperature to prepare a catheter loaded with acrinol. Obtained. When the obtained catheter was subjected to the same test as in Example 1, an inhibition circle occurred in the 40-day Ho test.

Patent applicant: Unitika Co., Ltd. 29-

Claims (1)

[Claims] (1) In the inner or outer wall of a urinary catheter made of an olefin polymer, diene polymer, or silicone polymer, ■maleic anhydride and an aromatic vinyl 7-mer olefin monomer that can be copolymerized with maleic anhydride. 1 (per 100 parts by weight of the total amount of component N and component B)
~200 parts by weight of the polyfunctional compound (C) to form a film having unreacted maleic anhydride groups on the inner or outer wall, and then some or all of the maleic anhydride groups are removed. A method for producing a urinary catheter having the ability to prevent urinary tract infection, which comprises bonding an odoriferous substance to the membrane after hydrolysis.